Leukemia drug holiday: study tests if patients can pause treatment
NCT ID NCT04626024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether people with chronic myeloid leukemia (CML) who have had a stable, deep response to treatment for at least two years can safely stop taking their daily targeted therapy (TKI). It involves 17 adults who have been on TKI for over three years. The main goal is to see how many remain relapse-free six months after stopping the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine- McNair Campus
Houston, Texas, 77030, United States
-
Ben Taub General Hospital
Houston, Texas, 77030, United States
-
CHI St. Luke's Health Baylor College of Medicine Medical Center
Houston, Texas, 77030, United States
-
Harris Health System- Smith Clinic
Houston, Texas, 77054, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Could bone marrow from deceased donors cure blood cancers?
- New hope for young adults with CML: asciminib under Real-World scrutiny
- Engineered t cells with a kill switch aim to make stem cell transplants safer
- Real-World data reveals how bosutinib fights leukemia outside clinical trials
- Could cousins be as good as siblings for stem cell donation?